Novo Nordisk A/SNVONYSE
Loading
Year-over-year operating income growth rate
Latest
33.54%
↑ 703% vs avg
Percentile
P90
Near historical high
Streak
1 qtr
Consecutive growthAccelerating
Average
4.18%
Historical baseline
| Period | Value |
|---|---|
| Q4 2025 | 33.54% |
| Q3 2025 | -29.20% |
| Q2 2025 | -13.77% |
| Q1 2025 | 5.59% |
| Q4 2024 | 8.62% |
| Q3 2024 | 30.42% |
| Q2 2024 | -18.56% |
| Q1 2024 | 18.98% |
| Q4 2023 | -0.55% |
| Q3 2023 | 12.66% |
| Q2 2023 | -4.47% |
| Q1 2023 | 46.35% |
| Q4 2022 | -15.34% |
| Q3 2022 | 9.75% |
| Q2 2022 | -3.95% |
| Q1 2022 | 40.44% |
| Q4 2021 | -10.59% |
| Q3 2021 | 3.18% |
| Q2 2021 | -1.35% |
| Q1 2021 | 34.03% |
| Q4 2020 | -12.73% |
| Q3 2020 | -7.44% |
| Q2 2020 | -15.11% |
| Q1 2020 | 37.30% |
| Q4 2019 | -8.10% |
| Q3 2019 | -3.96% |
| Q2 2019 | -5.53% |
| Q1 2019 | 32.05% |
| Q4 2018 | -8.72% |
| Q3 2018 | -3.20% |
| Q2 2018 | -1.96% |
| Q1 2018 | 23.90% |
| Q4 2017 | -16.58% |
| Q3 2017 | -10.03% |
| Q2 2017 | -0.77% |
| Q1 2017 | 20.38% |
| Q4 2016 | -9.77% |
| Q3 2016 | -0.62% |
| Q2 2016 | 1.53% |
| Q1 2016 | 10.64% |